ABOUT this BLOG and How to use it

WELCOME to Stu's Views & MS News. A product of MS Views and News, a Not-for-Profit [501c3] organization. Founded in 2008, we provide educational Multiple Sclerosis information via live seminars and via the internet.

Key-Notes: Our live seminars average approx 60 people per educational program. Our blog is visited over 2900 times per week and our website is visited by thousands each month.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in (90) Countries.

On this blog see our Directory, Archives, recent Blog Posts & so much more. Use the Blog Search box (enter a keyword). See our Facebook information AND Links to other MS Organizations & bloggers. Scroll through entire page, to find information that could EMPOWER You. At the Bottom of this page, see informational videos and some for fun.

Disclaimer: "Stu's Views & MS News" / 'MS Views and News' does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Like this blog? - CLICK "LIKE"

Friday, April 8, 2011

Laquinimod, Alemtuzumab, CCSVI, and much more, to be discussed at the AAN meeting in Hawaii, April 9th thru 16th



Showing just a few of what will be discussed: 
 
Teva to present Laquinimod data at Hawaii conference
Globes Online Thu, 07 Apr 2011 09:21 AM PDT
The Phase III trial of the oral multiple sclerosis drug showed a statistically significant reduction in annualized relapse rate and in the disability progression.

Press Release
PharmiWeb Thu, 07 Apr 2011 08:04 AM PDT
Genzyme , a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis (MS) at the American Academy of Neurology's (AAN) 63rd Annual Meeting in Hawaii, April 9 - 16, 2011. Included among the additional Phase 2 trial safety and efficacy data at AAN ...
Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy Of Neurology
Business Wire Thu, 07 Apr 2011 06:21 AM PDT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis (MS) at the American Academy of Neurology's (AAN) 63rd Annual Meeting in Hawaii, April 9 - 16, 2011. Included among the additional Phase 2 trial ...
 
 
Press Release
PharmiWeb Fri, 08 Apr 2011
EMD Serono Inc. Posted on:08 Apr 11 EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis (MS) portfolio will be presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) taking place from April 9 to 16, in Honolulu, Hawaii.


****************************************************************
Remain CURRENT with Multiple Sclerosis information 
 when registered at the  MS Views and News  website
.
***************************************************************************************
Help to Educate:  Please donate   - all contributions are tax deductible - 
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
 ****************************************************************

0 comments: